Roflumilast in severely ill patients with chronic obstructive pulmonary disease with frequent exacerbations: real-life outcomes
I. Alispahic (Hellerup, Denmark), R. Sørensen (Copenhagen, Denmark), J. Eklöf (Hellerup, Denmark), P. Sivapalan (Hellerup, Denmark), A. Løkke (Vejle, Denmark), N. Seersholm (Hellerup, Denmark), J. Vestergaard (Hellerup, Denmark), C. Bergsoe (Hellerup, Denmark), J. Jensen (Hellerup, Denmark), (Hellerup, Denmark)
Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD
Session: Clinical and basic pharmacology for COPD
Session type: E-poster session
Number: 178
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Alispahic (Hellerup, Denmark), R. Sørensen (Copenhagen, Denmark), J. Eklöf (Hellerup, Denmark), P. Sivapalan (Hellerup, Denmark), A. Løkke (Vejle, Denmark), N. Seersholm (Hellerup, Denmark), J. Vestergaard (Hellerup, Denmark), C. Bergsoe (Hellerup, Denmark), J. Jensen (Hellerup, Denmark), (Hellerup, Denmark). Roflumilast in severely ill patients with chronic obstructive pulmonary disease with frequent exacerbations: real-life outcomes. 178
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: